CliffBio
small molecule

MIRABEGRON

MIRABEGRON

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameMIRABEGRON
Active ingredientMIRABEGRON
Strength25MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2022
Marketing statusRX

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.